• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HAN Chun, WU Lintao, HU Xiaoqin, SUN Long, HUANG Zhangjian, ZHANG Yihua. Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates[J]. Journal of China Pharmaceutical University, 2018, 49(1): 48-55. DOI: 10.11665/j.issn.1000-5048.20180107
Citation: HAN Chun, WU Lintao, HU Xiaoqin, SUN Long, HUANG Zhangjian, ZHANG Yihua. Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates[J]. Journal of China Pharmaceutical University, 2018, 49(1): 48-55. DOI: 10.11665/j.issn.1000-5048.20180107
shu

Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates

More Information
    Graphical Abstract
    • Abstract
  • To search for potent drugs against non-small-cell lung cancer(NSCLC), a series of hybrids( 9a - 9e , 10a - 10e and 11a - 11e) from anilinopyrimidines and diazeniumdiolates were designed and synthesized. The MTT assay was employed to evaluate their antiproliferative activity against H1975 cells harboring epithelial growth factor receptor(EGFR)L858R/T790M mutation. The results showed that compounds 9a - 9e displayed remarkable inhibitory activity on H1975 cells. Among these compounds, the most potent was compound 9b (IC50=0. 65 μmol/L), which was superior to the positive control gefitinib. Additionally, molecular docking study indicated that 9b could bind with EGFR T790M by forming hydrogen bond, electrostatic interactions, et al, suggesting that compound 9b may be a potential anti-NSCLC agent for further investigation.
    • FullText(HTML)
    • References (16)
  • [1]
    Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
    [2]
    Herbst RS,Heymach JV,Lippman SM.Lung cancer[J].N Engl J Med,2008,359(13):1367-1380.
    [3]
    Johnson BE,Janne PA.Epidermal growth factor receptor mutations in patients with non-small cell lung cancer[J].Cancer Res,2005,65(17):7525-7529.
    [4]
    Govindan R.A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer[J].Clin Lung Cancer,2010,11(1):8-12.
    [5]
    Finlay MR,Anderton M,Ashton S,et al.Discovery of a potent and selective EGFR inhibitor(AZD9291)of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor[J].J Med Chem,2014,57(20):8249-8267.
    [6]
    Walter AO,Sjin RT,Haringsma HJ,et al.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC[J].Cancer Discov,2013,3(12):1404-1415.
    [7]
    Zhou W,Ercan D,Chen L,et al.Novel mutant-selective EGFR kinase inhibitors against EGFR T790M[J].Nature,2009,462(7276):1070-1074.
    [8]
    Basudhar D,Ridnour LA,Cheng R,et al.Biological signaling by small inorganic molecules[J].Coord Chem Rev,2016,306(Pt 2):708-723.
    [9]
    Huang Z,Fu J,Zhang Y.Nitric oxide donor-based cancer therapy:advances and prospects[J].J Med Chem,2017,60(18):7617-7635.
    [10]
    Cheng H,Wang L,Mollica M,et al.Nitric oxide in cancer metastasis[J].Cancer Lett,2014,353(1):1-7.
    [11]
    Han C,Huang Z,Zheng C,et al.Novel hybrids of(phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer[J].J Med Chem,2013,56(11):4738-4748.
    [12]
    Han C,Huang Z,Zheng C,et al.Nitric oxide donating anilinopyrimidines:synthesis and biological evaluation as EGFR inhibitors[J].Eur J Med Chem,2013,66:82-90.
    [13]
    Han C,Wan L,Ji H,et al.Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growthfactor receptor inhibitors[J].Eur J Med Chem,2014,77:75-83.
    [14]
    Huang Z,Kaur J,Bhardwaj A,et al.O2-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl(HNO)donors:synthesis,beta-elimination fragmentation,HNO release,positive inotropic properties,and blood pressure lowering studies[J].J Med Chem,2012,55(22):10262-10271.
    [15]
    Hong SY,Saavedra JE,Keefer LK,et al.Improved synthesis of V-PYRRO/NO,a liverselective nitric oxide prodrug,and analogues[J].Tetrahedron Lett,2009,50(18):2069-2071.
    [16]
    Hamann JN,Rolff M,Tuczek F.Monooxygenation of an appended phenol in a model system of tyrosinase:implications on the enzymatic reaction mechanism[J].Dalton Trans,2015,44(7):3251-3258.
    • Related Articles

  • Related Articles

    [1]LIU Li, LIU Zijin, TANG Jun, HE Guangwei, LIU Weizhong. Optimized synthesis process of tofacitinib citrate[J]. Journal of China Pharmaceutical University, 2022, 53(6): 685-689. DOI: 10.11665/j.issn.1000-5048.20220606
    [2]WU Xufeng, CHAI Shiying, LIU Jianhong, WANG Zhihui, YIN Ruifeng, CAO Ruiwei, SUN Xinqiang. Improvement of synthetic route of brivudine[J]. Journal of China Pharmaceutical University, 2022, 53(1): 41-45. DOI: 10.11665/j.issn.1000-5048.20220106
    [3]WANG Dong, ZHONG Jian, WANG Ling, ZHOU Zhihui, JIANG Haiting, LUO Peng, WANG Xizhi, WANG Chongyi. Improved synthetic process of apremilast[J]. Journal of China Pharmaceutical University, 2021, 52(5): 536-540. DOI: 10.11665/j.issn.1000-5048.20210504
    [4]HAN Chengqun, ZOU Qiaogen, SUN Qian, XIA Yunyan. Improvement of synthesis process of mirabegron[J]. Journal of China Pharmaceutical University, 2020, 51(4): 449-453. DOI: 10.11665/j.issn.1000-5048.20200409
    [5]ZHANG Qiuyue, YOU Qidong, YANG Jinpeng. Process improvement on the synthesis of atomoxetine[J]. Journal of China Pharmaceutical University, 2019, 50(4): 405-409. DOI: 10.11665/j.issn.1000-5048.20190404
    [6]LIU Li, WANG Chen, LIU Lixin, JI Tingting. Improved synthesis of analgesic pentazocine[J]. Journal of China Pharmaceutical University, 2018, 49(5): 568-571. DOI: 10.11665/j.issn.1000-5048.20180508
    [7]MA Li, ZHANG Menghan, XU Zhiwei, SUN Ying′ai, ZHU Jing, HUANG Yingbo, ZHANG Dayong. A new synthetic process of dapagliflozin[J]. Journal of China Pharmaceutical University, 2017, 48(1): 42-45. DOI: 10.11665/j.issn.1000-5048.20170106
    [8]WEI Qingjie, QIAO Junhua, CHEN Jianjun, GAO Zhigang, LI Yaqing. An improvement for synthesis of ceftriaxone sodium[J]. Journal of China Pharmaceutical University, 2016, 47(2): 163-165. DOI: 10.11665/j.issn.1000-5048.20160206
    [9]Improve on the Synthetic Process of Bezafibrate[J]. Journal of China Pharmaceutical University, 2003, (3): 80-81.
    [10]Improved Process of Nimodipine[J]. Journal of China Pharmaceutical University, 1998, (3): 82-83.

  • Cited by

    Periodical cited type(3)

    1. 李雨晴，邹师琪，傅伟淇，杨欣. 基于网络药理学和分子对接探讨陈皮治疗非小细胞肺癌的作用机制. 中华生物医学工程杂志. 2024(04): 266-272 .
    2. 高杰，丁留成，卫中庆. 脂质代谢在去势抵抗性前列腺癌中的研究进展. 东南国防医药. 2021(02): 169-174 .
    3. 赵帅华，董卫红，杨敬，韩保卫. ABHD5过表达对结肠癌细胞侵袭、迁移及AMPK/mTOR通路的影响. 中国普外基础与临床杂志. 2021(07): 850-855 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(5)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：366149

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return